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Introduction
Asthma and wheezing in children is a common problem and 
the last 20 years has seen its prevalence rise from 5% to almost 
20% of the pediatric population in Pakistan.1 Hospitalizations 
have increased eightfold in that time despite increasing use 
of inhalers and better delivery of medications via spacers and 
aerochambers. Whether the increased prevalence of asthma relates 
to environmental factors (as seems likely), the most likely trigger 
for individual attacks is a viral infection.2 Parental perception 
that various allergens account for asthma symptoms, the role 
of RAST testing, IgE, and skin testing to pinpoint a particular 
avoidable allergen is at best disappointing. House dust mite is the 
usual offender and it is practically possible to eradicate it from our 
houses by getting rid of carpets and by plastic covering of beddings 
and pillows.3 
The diagnosis of asthma in under 2 year olds with persistent 
or recurrent wheezing and cough is difficult and the term “post-
bronchiolitis wheezing” or “wheezy bronchitis” is often used. If 
there are prolonged wheezy symptoms following viral infections, 
and an evidence of atopy or a family history of atopy, then one 
should consider asthma in this age group.4 
Asthma in older children is evidenced by a characteristic 
history of viral upper respiratory tract infection (URTI) induced 
coughing with or without wheeze with the coughing being 
nocturnal or exercise-induced and non-productive in nature. 
Early morning coughing is also characteristic. Other symptoms of 
atopy such as eczema or allergic rhinitis frequently coexist. Chest 
tightness or chest pain may also occur.5
Differential Diagnosis of Asthma
Because of its increasing prevalence, it is important to consider 
differential diagnosis that may mimic asthma or may coexist in 
asthmatic children.6 Inhaled foreign bodies (usually peanuts or 
beatlenuts) may present with acute shortness of breath or wheeze 
in a previously well toddler. Gastroesophageal reflux may present 
with repeated respiratory symptoms.7 
Cystic fibrosis may have associated wheeze (up to 40%) and if 
there are any suggestive features (nasal polyps, steatorrhea, failure 
to thrive or failure to respond to routine asthma medication) 
it should be considered. Tuberculosis needs to be considered 
and excluded. Habit or psychogenic cough is quite common and 
presents with a barking, seal-like cough which is very disruptive to 
school and family life.8 
The adage “all that wheeze is not asthma” is most certainly 
true but if you find that your treatment strategy is not working, 
you need to consider the above differential diagnosis. The vast 
majority of asthma in the community is diagnosed and correctly 
managed by family doctors and most referrals to Pediatricians are 
to reassure parents that the diagnosis is asthma and to perhaps add 
a little in terms of an asthma plan.      
Treatment of Acute Asthma
Recent guidelines (GINA) are very helpful and provide up to 
date consensus guidelines. This report focuses on some perhaps 
controversial aspects of asthma management.9
Beta 2 agonists: Randomized controlled trials have proven that 
these are both safe and efficacious. Inhalation of short-acting beta 
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agonists leads to a very rapid response, generally within minutes 
and the effects last for 3-4 hours.10 Only about 10-15% actually 
enters the lungs with much of the remainder being swallowed. Use 
of aerochamber is recommended for up to 3 years of age with the 
large volume spacer being used in the 3-5 yrs age groups. It has 
been shown that large volume spacers are as effective as nebulizers 
in moderate acute asthma if used correctly.
However, we feel that oral salbutamol or terbutaline should 
be avoided because of its very limited efficacy and in terms of age, 
appropriate use of aerochambers and volumatics to deliver beta 2 
agents gives excellent drug delivery to the airways. Also, prescribing 
a home nebulizer for beta 2 agonist use should only be done in 
exceptional circumstances (e.g. previous life-threatening asthma). 
Thus, large volume spacers are as effective as nebulizers in treating 
acute moderate asthma and if a parent requires giving more than 4 
hourly beta 2 agents in an acute asthma attack, the patient should 
be reviewed and referral to hospital should be considered.
Anticholinergics: These are not the first line bronchodilators but 
may provide additive benefit when combined with beta 2 agonists. 
Ipratropium bromide (atrovent) is the most commonly used 
anticholinergic in clinical practice and its onset is slower (30-60 
minutes) but the duration of its effects is longer (>4 hours). It is 
remarkably free of unwanted side effects.10
However, it can be proposed that Ipratropium may be added 
to salbutamol in moderate/severe acute asthma with beneficial 
effect. Although frequently given, there is no proven benefit of 
using ipratropium in acute bronchiolitis. Hence, it is a very safe 
medication, virtually free of side effects because of its local action
Corticosteroids: Inflammation has a major role in the 
pathophysiology of acute asthma and thus steroid use can be 
justified.11 Oral or intravenous corticosteroids take over 4 hours 
to become effective and short courses of corticosteroids are 
recommended for acute asthma episodes.10 The administration of 
corticosteroids by the oral route is as efficacious as the intravenous 
route and oral prednisolone 1 mg/kg/day for 5 days given as a 
single daily dose is recommended. Hence, no tail off in steroid dose 
is required for children in short term use. Inhaled or nebulized 
steroids use is justified in acute moderate asthma.  
Theophyllines: Theophylline has a narrow therapeutic index and 
adverse effects such as tremor, nausea, vomiting, tachycardia, 
headaches and abdominal pain occur frequently in patients treated 
for acute asthma exacerbations.6 Oral slow release theophyllines 
are occasionally beneficial in children with troublesome nocturnal 
cough. Moreover, intravenous aminophylline in acute severe 
asthma has a sustained benefit on oxygenation but at a cost of 
frequent side effects. The narrow therapeutic index precludes the 
widespread use of theophylline derivatives.
Long Term Asthma Treatment in the Community
The great majority of asthmatics (over 80%) have infrequent 
episodic asthma (less than 4 attacks per year) and require only beta 
2 agents +/- steroids for acute exacerbations. Those with frequent 
episodes (>4 episodes per year) and persistent asthma do require 
preventative treatment. The goalposts have changed recently with 
the addition of long-acting beta 2 agents such as salmeterol and the 
recent advent of leukotriene modifiers.6 This review highlights the 
update on their use.
Sodium cromoglycate: Sodium cromoglycate inhibits mast cell 
degranulation and its primary advantages are its minimal side 
effects and the fact that it is well known, having been on the 
market for over 30 years. It has been sidelined of late and is now 
infrequently prescribed.12 Recommendations to set up therapy 
with the addition of sodium cromoglycate to intermittent beta 2 
agonists for children with frequent episodic asthma and then to 
replace cromoglycate with low dose steroids if no response within 
6 weeks is evidence-based.12 Perhaps parents of today are unwilling 
to wait 6 weeks for an anticipated response!
In pre-school children, there is less clear supportive evidence 
for the effectiveness of sodium cromoglycate, and in this situation 
it would seem preferable to use inhaled corticosteroids.4
Parents are anxious about potential side effects of inhaled 
steroids and their concerns need to be addressed by using the 
lowest dose possible and stepping up or down treatment as 
required. Inhaled moderate dose (i.e less than 600 micrograms/
day) beclamethasone dipropionate is unlikely to have a clinically 
significant effect on linear growth and this dose should be 
considered safe.13 Growth restriction has not been found in three 
long term studies of fluticasone dipropionate and several studies 
have shown that, in school-aged children who require inhaled 
steroids to control their asthma symptoms, growth restriction was 
more often associated with beclamethasone and budesonide then 
with fluticasone.14 
Long acting beta agonists (salmeterol): The bronchodilator 
activity of salmeterol lasts for up to 12 hours, as compared with 
4 to 5 hours for short-acting beta agonists. Although salmeterol 
50 micrograms twice daily provides significant improvement in 
lung function compared with placebo or ‘as needed’ salbutamol, 
Asthma in Children Management... Ahmed et al.
255Oman Medical Journal 2010, Volume 25, Issue 4, October 2010
beclamethasone 400 micrograms per day is more effective than 
salmeterol.15 We feel one should consider salmeterol for children 
receiving optimal inhaled corticosteroid therapy who continue to 
experience symptoms requiring frequent bronchodilator therapy. 
Salmeterol should not be used as a rescue medication and its role 
in long term monotherapy is controversial and unproven.
Leukotriene modifiers: Leukotrienes are potent broncho-
constrictors and antileukotriene drugs are either receptor 
antagonists or enzyme inhibitors.  Early studies of leukotriene 
receptor antagonists (e.g. montelukast) have shown improvement 
in lung function, decreased frequency of asthma exacerbations and 
improved quality of life. 
Montelukast has a rapid onset of action (1 day) and adverse 
effects seen include headache, pharyngitis and abdominal pain. It 
is taken as a single dose at bedtime. The safety profile is not as 
yet well-established and whether compliance is improved with oral 
therapy, as compared to inhaled therapy, is not yet known.16 
We would suggest that leukotriene receptor antagonists be 
used in situations where one wishes to avoid the use of high dose 
inhaled steroids to control symptoms and in this instance, they 
would be used in addition to low dose inhaled steroids.17 
Conclusion
The marked increase in the prevalence of asthma, increased 
hospitalizations and the soaring drug budget for anti-asthma 
medications all point to a condition that we do not truly 
understand. It is tempting to state that children grow out of 
asthma but the evidence shows that the majority remain asthmatic 
into adulthood. The epidemiology is poorly understood in the 
developing world and new treatment regimens are coming into the 
market.18 The aim of ‘primum no nocere’ (‘first do not harm’) is apt 
and one should always aim for relief of symptoms with minimum 
medication. 
Asthma control should ensure those troublesome symptoms 
are prevented both night and day and serious attacks are prevented. 
Patients require less quick-relief beta 2 agonist medication and to 
have (near) normal lung function, but most importantly, to be able 
to lead productive, physically active lives. 
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